Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Abeona Therapeutics (ABEO) over the last 14 years, with Q3 2025 value amounting to $54.2 million.

  • Abeona Therapeutics' Shares Outstanding (Weighted Average) rose 1281.31% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year increase of 1281.31%. This contributed to the annual value of $41.0 million for FY2024, which is 9198.92% up from last year.
  • Per Abeona Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $54.2 million for Q3 2025, which was up 1281.31% from $52.5 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Shares Outstanding (Weighted Average) registered a high of $94.2 million during Q1 2021, and its lowest value of $3.9 million during Q2 2021.
  • Over the past 5 years, Abeona Therapeutics' median Shares Outstanding (Weighted Average) value was $21.4 million (recorded in 2023), while the average stood at $27.7 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Shares Outstanding (Weighted Average) plummeted by 9583.11% in 2021, and later surged by 28618.0% in 2023.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Shares Outstanding (Weighted Average) stood at $3.9 million in 2021, then surged by 99.65% to $7.9 million in 2022, then skyrocketed by 171.96% to $21.4 million in 2023, then surged by 91.99% to $41.0 million in 2024, then skyrocketed by 32.14% to $54.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $54.2 million for Q3 2025, versus $52.5 million for Q2 2025 and $49.8 million for Q1 2025.